Swiss pharmaceutical giants Novartis has received a huge blow to its Indian operations after the country’s Supreme Court dismissed a patent request for its cancer drug, Glivec.
Swiss pharmaceutical giants Novartis has received a huge blow to its Indian operations after the country’s Supreme Court dismissed a patent request for its cancer drug, Glivec. The Supreme Court ruled that the compound for which Novartis was seeking a patent "did not satisfy the test of novelty or inventiveness" required by Indian law.
Source-AFP